TNFRSF8 and neoplasm: In this study, we recombinatorily expressed the CD30 protein fragment using tumor tissue from CD30-positive PTCL patients and prepared the monoclonal antibody against the CD30 protein fragment; the hope was that the CD 30 mAb would be compatible with the PTCL patients that were positive for CD30.